AvonBC logo_RGBAvon Breast Cancer Crusade

Since 1992, the Avon Breast Cancer Crusade has been working to help to prevent, treat, and ultimately eradicate breast cancer.

The Crusade seeks to improve breast cancer outcomes and reduce disparities in survival rates at the community and national levels. Strategic grant making reflects: a holistic and place-based approach in high-need areas throughout the United States; a commitment to enabling access to medical advances and support services for breast cancer patients, particularly those from vulnerable populations; and a commitment to investing in research on the prevention, diagnostics, and treatment of breast cancer.

The Avon Foundation for Women administers programs in the United States and partners with affiliate Avon Foundations and Avon markets around the world. In the U.S., Avon Breast Cancer Crusade LLC manages this breast cancer work. In total, Avon and the Foundation have contributed more than $800 million to breast cancer programs around the world through 2016.



AVON 39 The Walk To End Breast Cancer

AVON 39 The Walk To End Breast Cancer, a project of the Avon Breast Cancer Crusade, takes place in seven U.S. cities and covers 39.3 miles in two days and is the largest fund-raising event for the Avon Breast Cancer Crusade. Visit www.avon39.org for more information.


Access to Care Programs

In 2016, Avon funded “access to care programs” and provided patients with nearly 437,000 educational contacts, and enabled access to 248,000 mammograms and other diagnostics.  Programs provided more than 129,000 patient navigation services to over 70,000 medically underserved individuals. Findings demonstrate that Patient Navigation works best in low resource hospital systems, where barriers to healthcare exist. Navigators help patients to overcome these challenges including lack of transportation, insurance or finances. Patient Navigation programs are funded by the following initiatives:

Since inception, the Avon Breast Cancer Crusade has facilitated more than 12 million educational encounters through the Avon Breast Health Outreach Program, which supports community-based organizations across the U.S. to provide culturally competent education and outreach, and link underserved individuals to early detection programs and risk reduction strategies.

The Avon Breast Cancer Crusade supports patient navigator programs at Safety Net Hospitals to help patients understand and overcome the complex medical maze faced after receiving an abnormal screening or breast cancer diagnosis and the challenges in securing access to high-quality and timely treatment. Since inception, Avon Access to Care Programs have awarded more than 790 grants through the end of 2016, totaling more than $235 million, to more than 200 hospitals across the country. The goal of these programs is to help women and men who might fall through the cracks of the healthcare system gain access to quality breast cancer services and the most current medical advances.

Funding supports seven Avon Comprehensive Breast Care Centers of Excellence, all located at major academic medical centers. Avon grants enable these Centers to develop new programs to reach and treat underserved populations in their communities and provide them direct access to the cutting-edge advancements in treatment and care that are being developed at these same institutions.

Support Programs

Launched in 2000, the AVONCares Program at CancerCare has reached medically underserved breast cancer patients living in 96% of all U.S. counties, providing more than 85,000 women and men with financial assistance to help access care. All clients assisted are introduced to CancerCare’s other free services, including counseling, education and referrals to key resources.

Since 2001, Avon has made more than 70 grants totaling more than $12 million to nutrition programs across the country that have provided nutrition counseling, education, grocery services and millions of home-delivered meals to women fighting breast cancer and their dependents. Hunger and malnutrition contribute to medical complications, repeat hospitalizations, and higher mortality rates for the critically ill and these important nutrition services play a significant role in recovery and prevention.

Metastatic Breast Cancer Focus

Avon and Pfizer partnered on the Metastatic Breast Cancer Grants Program: Identify – Amplify – Unify, which provided a total of $1 million in grants to support 23 non-profit organizations developing programmatic solutions to challenges experienced by metastatic breast cancer patients and their caregivers. Another $1 million, for a total of $2 million, was granted to 22 non-profit organizations for programs in 2017. This partnership put into action recommendations from recent expert panels and studies on quality of life issues of patients, identifying the needs of metastatic breast cancer patients, amplifying awareness and resources, and unifying the metastatic breast cancer community. Read an executive summary of best practices and lessons learned from the 2015-2016 program. You can also learn more about this work in our white paper.

Research Initiatives

The Avon Breast Cancer Crusade supports breast cancer research through grant funding, as well as by providing scientific coordination and fostering collaboration between its funded programs. Since inception, the Avon research initiative has invested  more than $200 million in projects to drive advancements in biomarkers, diagnostics, prognostics, genetics, disparities, the role of environmental factors in the development of breast cancer, the connection between parity status and breast cancer risk, better or new treatments, the role of viruses and immunology, and metastasis and metastatic disease.

Current research priorities include:

  • Understanding the causes of breast cancer and finding ways to prevent it.
  • Developing new treatments for under-investigated areas of research, such as metastatic breast cancer and rare, aggressive types of the disease (including inflammatory breast cancer and triple negative breast cancer).